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Bone marrow-derived mononuclear cells (BM-MNCs) were shown to improve the
outcome in animal stroke models and clinical pilot studies on BM-MNCs for stroke
patients were already conducted. However, relevant aspects of pre-clinical evaluation,
such as the use of animals with comorbidities and dose-response studies, were not
thoroughly addressed so far. We therefore investigated different BM-MNC doses in
the clinical meaningful stroke model of spontaneously hypertensive (SH) rats. Three
hours after the onset of transient middle cerebral artery occlusion (MCAO) animals
received either one of three syngeneic BM-MNC doses or placebo intravenously. The
primary endpoint was the infarct size. Secondary endpoints included functional outcome,
mortality, inflammatory processes, and the dose-response relationship. In contrast to
previous studies which used healthy animals no beneficial effect of BM-MNCs was found.
Infarct volumes, mortality, behavioral outcomes, and the extent of the inflammatory
response to cerebral ischemia were comparable in all groups. In conclusion, we could not
demonstrate that early BM-MNC treatment improves the outcome after stroke in SH rats.
Whether BM-MNCs improve neurological recovery after delayed treatment initiation was
not investigated in the present study, but our data indicates that this should be determined
in co-morbid animal stroke models before moving to large-scale clinical studies. Future
preclinical stroke studies on co-morbid animals should also include groups of healthy
animals in order to determine whether negative results can be attributed to the comorbid
condition.
Keywords: bone marrow-derived mononuclear cells, middle cerebral artery occlusion, stroke, dose-response,
spontaneously hypertensive rats
INTRODUCTION
Cell based therapies have been proposed as means of treating
stroke. Among the different cell types under investigation for
stroke, bone marrow-derived mononuclear cells (BM-MNCs)
represent a particularly attractive treatment option. BM-MNCs
can be easily obtained by bone marrow aspiration, do not
require extensive preparation or cultivation, and permit autol-
ogous intravenous transplantation (Savitz et al., 2011b). Within
the last several years, a number of reports showed that BM-MNCs
reduce neurological impairment in animal models of focal cere-
bral ischemia after application in the acute and subacute phases
(Iihoshi et al., 2004; Kamiya et al., 2008; Giraldi-Guimarães et al.,
2009; Brenneman et al., 2010; Nakano-Doi et al., 2010). BM-
MNC mediated neurological improvements including reduction
of the final lesion volume, attenuated microglial activation, and
promoted recovery after the initial ischemic event (Brenneman
et al., 2010; Nakano-Doi et al., 2010; Sharma et al., 2010).
Recent evidence suggests that BM-MNCs mediate their actions
by the production and secretion of cytokines (Sharma et al.,
2010). These in turn modulate the post-ischemic inflammatory
response and attenuate neuronal cell death (Brenneman et al.,
2010; Sharma et al., 2010; Wagner et al., 2012). Giving results from
previous investigations reporting highest efficacy after BM-MNC
transplantation within 3 h, early neuroprotective effects may be
responsible for the majority of observed benefits (Iihoshi et al.,
2004; Brenneman et al., 2010).
Recently, an open-label prospective study showed that intra-
venous BM-MNC treatment is safe and feasible in acute stroke
patients (Savitz et al., 2011b). However, the pre-clinical package
that is recommended to work up before proceeding to larger
clinical efficacy studies has not been completed yet. For exam-
ple, the Stroke Therapy Academic Industry Roundtable (STAIR)
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and The Stem Cell Therapies as an Emerging Paradigm in Stroke
(STEPS) recommendations stress the importance of testing can-
didate cell therapies in animals with comorbidities (Fisher et al.,
2009; Stem Cell Therapies as an Emerging Paradigm in Stroke
Participants, 2009; Savitz et al., 2011a). Such studies are lacking
for BM-MNC so far. This is remarkable given that the majority
of stroke patients have comorbidities, such as hypertension.
Moreover, analyzes of previous animal stroke studies revealed
that experiments with healthy animals compared to those using
animals with comorbidities overstated the efficacy of a given
treatment (Crossley et al., 2008). Pre-clinical cell dose-response
investigations are not only requested by the STAIR and STEPS
guidelines but also recommended by the US Food and Drug
Administration (FDA) to be performed prior to initiating a clini-
cal trial.1
Here, we investigated the neuroprotective properties of sys-
temically transplanted BM-MNCs on infarct size, functional
outcome, and glial inflammatory processes as well as their dose-
response relationship in spontaneously hypertensive (SH) rats
with focal cerebral ischemia at 3 h following stroke, for which




All animal procedures were approved by the responsible ethics
committee of the University of Münster and the appropriate
authorities of the Federal State of North Rhine-Westphalia.
The investigations were carried out in accordance with national
and international animal welfare regulations and are reported
in accordance with the Animal Research: Reporting In Vivo
Experiments (ARRIVE) guidelines (Kilkenny et al., 2011). Surgery
and evaluation of all read-outs were performed blinded to exper-
imental groups. Experiments were performed on adult (12–13
weeks old) male SH rats weighing 260–290 g. SH rats were shown
to have an increased blood pressure starting from 5 to 6 weeks
of age (Dickhout and Lee, 1998). All animals were randomly
assigned to one of the following treatment groups: (1) placebo
(n = 19), (2) 1 million BM-MNCs/rat (n = 18), (3) 5 million BM-
MNCs/rat (n = 20), or (4) 20 million BM-MNCs/rat (n = 17).
The cell numbers used in our experiments were based on previous
studies that investigated different intravenous cell therapies in
animal stroke models (Iihoshi et al., 2004; Giraldi-Guimarães
et al., 2009; Minnerup et al., 2011). The condition of animals
was monitored at least every 8 h. Pre-defined termination criteria
were: (1) a severe immobility and (2) a persisting abnormal body
position. The implementation of these criteria was required by the
local ethics committee.
BONE MARROWMONONUCLEAR CELL PREPARATION
Syngeneic rat bone marrow was obtained from male SH rats at
the age of 12 weeks. Femurs and tibias were aseptically opened
and repeatedly flushed with phosphate buffered saline (PBS).
After erythrocyte lysis by ammonium chloride-based buffer
(0.155 M NH4Cl, 10 mM KHCO3 and 0.01 mM Na2EDTA)
1http://www.fda.gov/cber/guidelines.htm
cells were filtered by a 100 µm cell strainer, counted and
prepared for immunomagnetic depletion of granulocytes: 100
million bone marrow cells were incubated with 10 ng/ml
Phycoerythrin-conjugated anti-rat granulocyte antibody (clone
RP1; BD Pharmingen, Heidelberg, Germany) for 15 min at 4◦C.
Subsequently, cells were washed with cold PBS plus 0.5% fetal
calf serum (FCS) and incubated with 200 µl anti-Phycoerythrin
MicroBeads (Miltenyi Biotech, Bergisch Gladbach, Germany) in
800 µl PBS plus 5% FCS for 15 min at 4◦C. After incubation,
non-adsorbed MicroBeads were removed by a further washing
step. The cell suspension was then resuspended in 500µl PBS plus
0.5% FCS and magnetically separated by a LD-column according
to the manufacturer’s instructions (Miltenyi). This procedure
results in higher BM-MNC purity compared to standard den-
sity gradient centrifugation (Pösel et al., 2012). The obtained
mononuclear cell fraction was collected, counted, cryopreserved
in liquid nitrogen (25 million mononuclear cells in 1 ml FCS
plus 8% DMSO) and stored at −80◦C until further use. BM-
MNCs were labeled by PKH26 before transplantation (Zhang
et al., 2011).
STROKE MODEL AND CELL THERAPY
Animals were anesthetized by intraperitoneal injection of
ketamine hydrochloride (100 mg/kg body weight; Ketanest) and
xylazine hydrochloride (8 mg/kg body weight). The rectal tem-
perature was maintained at 37◦C by a thermostatically controlled
heating pad (Föhr Medical Instruments). Transient middle cere-
bral artery occlusion (tMCAO) was induced as described previ-
ously (Longa et al., 1989; Schäbitz et al., 2003). Briefly, following
a midline neck incision, a 3–0 nylon filament (Ethicon) with a tip
heated to form a bulb shape was inserted into the right common
carotid artery and advanced via the internal carotid artery to
occlude the origin of the right middle cerebral artery (MCA).
Cerebral blood flow was monitored continuously to verify MCA
occlusion and reperfusion using Laser-Doppler flowmetry (Peri-
flux 5001; Perimed, Stockholm, Sweden) with a probe positioned
over the MCA territory. After 60 min middle cerebral artery occlu-
sion (MCAO), the filament was withdrawn to allow reperfusion.
Three hours after onset of occlusion animals received the different
cell doses or vehicle intravenously.
BEHAVIORAL TESTING
After a 3 day training period, behavioral tests were performed
during the light cycle 1 day before MCAO (baseline), and at
24 and 72 h after ischemia. Functional outcome was studied
using the neurological score as described by Menzies (Menzies
et al., 1992). This score ranges from 0, indicating no deficit, to
4, indicating a severe neurological deficit (spontaneous circling).
For Rotarod tests, rats were placed on an accelerating Rotarod
cylinder, and the time the animals remained on this cylinder was
measured (Minnerup et al., 2010). Speed was increased from 4 to
40 rpm within 5 min. The trial ended if the animal fell off the
rungs or gripped the device and spun around for two consecutive
revolutions without attempting to walk on the rungs. An arbitrary
time limit of 300 s was set for rats on the Rotarod cylinder in
training and testing procedures. The mean duration (seconds) on
the device was recorded with three measurements 1 day before
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surgery. For the adhesive-removal test, the somatosensory deficit
was measured both before and after ischemia (Minnerup et al.,
2010). Two small pieces of adhesive-backed paper dots of equal
size were used as bilateral tactile stimuli occupying the palmar
surface of each forepaw. The rat was then returned to a cage. The
time to remove each stimulus from forelimbs was documented by
three trials per day for each forepaw (Schneider et al., 2005). For
the cylinder test, the rats were placed in a transparent cylinder
(16 cm diameter, 21 cm height) and videotaped from underneath
for 2 min (Minnerup et al., 2010). Spontaneous wall and ground
touches of the impaired contralateral forelimb were counted.
DETERMINATION OF INFARCT SIZE AND IMMUNOHISTOCHEMISTRY
Three days after ischemia, animals were anesthetized and tran-
scardially perfused with 4% paraformaldehyde in 0.1 mol/L phos-
phate buffer. The brains were fixed in 4% paraformaldehyde
at 4◦C and then cryoprotected in 30% sucrose solution. Tissue
was stored at −80◦C until analysis. For infarct size calculation,
10 µm serial coronal brain section were cut in a cryostat (Leica,
Nussloch, Germany), collected at 800 µm intervals and stained
with toluidine blue (Sigma, St. Louis, USA). Infarct volumes
were quantified with a standard computer assisted image analysis
technique. To correct for the effect of brain edema, a correc-
tion method was used as described previously (Sevimli et al.,
2009). For histological evaluation of inflammation, immuno-
histochemistry was performed on glass mounted coronal brain
sections (10 µm, approx. bregma −1 mm). After blocking of
non-specific proteins (using blocking reagent, 15 min, Roche
Diagnostics, Mannheim, Germany) the following primary anti-
bodies were applied (overnight, 4◦C): anti-GFAP (raised in
mouse, 1:500, Dako, Hamburg, Germany) and anti-Iba1 (raised
in goat, 1:200, Abcam, Cambridge, UK). To detect anti-GFAP-
antibodies we used a biotinylated goat anti-mouse antibody
(1:100, Jackson Labs, West Grove, PA, USA) for 45 min at
room temperature. Astrocytes were visualized by a streptavidin
conjugated fluorescent dye (AlexaFluor594, Molecular Probes,
Leiden, the Netherlands). For signal amplification of the Iba1
signal, brain slices were pre-treated with 3% H2O2/Methanol
for 10 min in order to block endogenous peroxidase. Detection
of Iba1-antibodies was performed using a biotin conjugated
donkey anti-goat antibody (1:200, 45 min, room temperature,
Jackson Labs, West Grove, PA, USA), followed by incubation
with horseradish peroxidase/streptavidin (1:100, 45 min, DAKO,
Glostrup, Denmark) and biotinyl tyramide, (1:100) for 10 min
at room temperature. Iba1-positive cells were visualized using
AlexaFluor594. A fluorescent-preserving mounting medium con-
taining 4′, 6-diamidino-2-phenylindole (DAPI) was used for
nuclear counterstaining (Vector, Burlingame, CA, USA). The
immunofluorescence signal was visualized with a fluorescent
microscope (Nikon Eclipse 80i microscope, Nikon GmbH, Dues-
seldorf, Germany) with appropriate filter sets for AlexaFluor594
and DAPI. Digitizing was done with a Stereo Investigator Soft-
ware (MicroBrightField Inc., Williston, VT, USA). To deter-
mine whether administered bone marrow-derived mononuclear
cells have an influence on the post-ischemic reactive astroglio-
sis, GFAP-stained sections (three randomly chosen animals per
group) were analyzed with respect to differences in morphology
FIGURE 1 | Infarct volumes 3 days after transient MCAO. Infarct volumes
did not differ between the four groups (n = 15–16/group). P = 0.595.
and immunoreactivity between the investigated groups. Quan-
tification of Iba1-posive cells was performed by counting and
averaging absolute cell amounts covering four random fields
(0.25 mm2 each) within the ipsilateral ischemic core and the
boundary zone of the infarct of two separate brain sections per
animal.
PRIMARY AND SECONDARY OBJECTIVES OF THE STUDY
According to the ARRIVE guidelines primary and secondary
objectives were defined.2 The primary endpoint was infarct size
measured on day 3 after ischemia. Secondary endpoints were
the functional outcome, mortality between treatment and day
3 (when animals were killed), inflammatory processes, and the
dose-response relationship.
STATISTICAL ANALYSIS
Values are presented as mean ± SD. The sample size (number
of animals per group) was calculated a priori with the following
assumptions: (1) infarct size reductions of ≥20% should be
detected, (2) a power of 0.8, (3) an α of 0.05, and (4) a SD
15% of the mean. A one-way analysis of variance (ANOVA) with
Tukey’s post-hoc test was used to compare of infarct volumes,
inflammatory processes, and physiological measures. Mortality
was compared using the chi-square test. Behavioral tests were
analyzed with two-way repeated-measures ANOVA. Statistical sig-
nificance was determined as an α error <0.05. Statistical analyses
were carried out using the Statistical Package of Social Sciences
(version 18).
RESULTS
MORTALITY AND PHYSIOLOGICAL MEASUREMENTS
There was no statistically significant difference in mortal-
ity between the four groups. A total of 11 animals died
until day 3: Three of the placebo group, 2 of the 1 mil-
lion BM-MNCs/rat group, 4 of the 5 million BM-MNCs/rat
2http://www.nc3rs.org/ARRIVE
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FIGURE 2 | Behavioral testing until day 3 after transient MCAO. No significant differences between the groups were detected in any of the functional
tests (n = 15–16/group). (A) Menzies score, P = 0.980. (B) Rotarod test, P = 0.670. (C) Adhesive-removal test, P = 0.922. (D) Cylinder test, P = 0.350.
group, and 2 of the 20 million BM-MNCs/rat group (P =
0.859). None of the animals met any of the termination cri-
teria. The animals died spontaneously due to the cerebral
ischemia. Rectal temperature, body weight, and cerebral blood
flow measurements were not different between groups (all P-
values > 0.05).
INFARCT VOLUMES
Infarct volumes did not differ between the four groups (placebo:
150.55 mm3 ± 23.11 mm3, 1 million BM-MNCs/rat: 148.74 mm3
± 39.90 mm3, 5 million BM-MNCs/rat: 145.59 ± 27.52 mm3,
20 million BM-MNCs/rat: 150.55 mm3 ± 23.11 mm3; P = 0.595;
Figure 1).
FUNCTIONAL OUTCOME
Functional outcomes as assessed by a behavioral test bat-
tery were not improved in any of the BM-MNC treated
groups (Figure 2) (Menzies score: P = 0.980, Rotarod test:
P = 0.670, adhesive-removal test: P = 0.922, cylinder test:
P = 0.350).
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FIGURE 3 | Transplanted cells in the brain. (A) Transplanted PKH26 positive
(red) BM-MNCs in the boundary zone of the infarct and in the infarct core.
Ipsilateral to the infarct BM-MNCs were located in the parenchyma, whereas
contralateral PKH26 positive cells were only detected in vessels. Overall, only
a few PKH26 positive cells were detected contralateral. Nuclei were
counterstained with 4′, 6-diamidino-2-phenylindole (DAPI, blue). (B) The map
depicts immigrated PKH26 positive cells within the infarcted hemisphere
(obtained from five animals).
ANALYSIS OF TRANSPLANTED BONE MARROW-DERIVED
MONONUCLEAR CELLS (BM-MNCs) AND POST-SCHEMIC
INFLAMMATION
Transplanted, PKH26 labeled cells were predominantly located
on the ischemic side of the brain and were sparsely detected
at the contralateral side. On the ischemic side, PKH26 positive
cells were located within the boundary zone of the ischemic
lesion (Figure 3). On the contralateral side BM-MNCs were only
detected in vessels.
Inflammation contributes to ischemic brain damage and BM-
MNCs were assumed to exert neuroprotective effects via anti-
inflammatory mechanisms (Dirnagl et al., 1999). We therefore
analyzed the extent of the glial inflammatory response. The
number of Iba1-positive cells with retracted processes and round
cell bodies, representing activated microglia, did not signifi-
cantly differ within the infarct core (P = 0.122) and within the
boundary zone of the infarct (P = 0.476) between the different
groups (Figure 4A). Pattern of astrocyte activation visualized by
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FIGURE 4 | Cellular inflammatory response 3 days after MCAO. (A) There
was no statistical difference between the groups regarding the number of
activated microglia cells (Iba1-positive) within the infarct core (P = 0.122) and
in the boundary zone (P = 0.476) of the infarct (n = 15–16/group). (B) GFAP
staining visualized the common distribution of astrogliosis surrounding the
infarcted tissue. No differences with respect to GFAP-immunoreactivity and
morphology between the BM-MNC and the placebo treated groups were
observed (n = 3/group).
GFAP-immunoreactivity was also comparable among all groups
(Figure 4B).
DISCUSSION
The present study did not show a beneficial effect for either
dose of BM-MNCs given intravenously 3 h after the onset of
focal cerebral ischemia in SH rats. There were no significant
effects on the primary and secondary end points. Infarct vol-
umes, mortality, behavioral outcomes, and the extent of the
inflammatory response to cerebral ischemia were comparable in
the placebo and in all BM-MNC groups. Particularly, no dose-
response relationship of BM-MNC treatment was found. Our
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results indicate that BM-MNCs do not exert acute neuropro-
tective properties in SH rats although transplanted BM-MNCs
reached the brain.
The efficacy of early BM-MNC treatment initiation within
6 h after stroke onset was investigated by a number of studies
(Iihoshi et al., 2004; Baker et al., 2007; Kamiya et al., 2008). For
intravenous cell administration, a higher efficacy of early BM-
MNC therapy at 3 h following stroke was shown as compared
to later treatment (Iihoshi et al., 2004). Moreover, recombi-
nant tissue-type plasminogen activator (rt-PA) treatment was
approved until 3 h after the onset of ischemia at the time when
the present study was designed (Hacke et al., 2008). Hence, the
time for cell therapy initiation seems to be reasonable from
a translational perspective. However, the sustained therapeutic
benefit of early intravenous BM-MNC application could not be
reproduced in our investigation, with the use of healthy animals
in aforementioned experiments being the major difference in
study design. Indeed, contrary results on a treatment’s efficacy
depending on the animal strain used in a study with greater infarct
size reductions in healthy animals compared to animals with
comorbidities were previously reported (Crossley et al., 2008).
This observation was even assumed to contribute substantially to
the translational failure in experimental stroke research (Crossley
et al., 2008). However, despite the use of hypertensive animals in
our study and the use of healthy animals in previously published
positive studies is the most obvious difference, our study does
not provide the final proof that the hypertensive condition of the
host or of the donor is the reason for the negative results, since
no healthy, non-hypertensive control group was included. Other
reasons such as the preparation of the BM-MNCs or the way of
cell transplantation might also be relevant for our negative results.
Baker et al. (2007) who also used healthy animals, found
reduced infarct volumes and improved functional outcomes after
early BM-MNC treatment (Baker et al., 2007). The intraarterial
administration of BM-MNCs in this study is a further main
difference to our experiments which might explain the contrary
results. Although intraarterial procedures after stroke are getting
more common and safer, results from a pre-clinical study found
that intraarterial cell therapy is associated with an increased
mortality (Walczak et al., 2008; Saver et al., 2012). From a
translational perspective, intravenous approaches therefore seem
to be the first choice in animal models and early-stage clinical
trials (Savitz et al., 2011b). So far, one previous study suggested
that systemic BM-MNC treatment may not be beneficial when
initiated after the onset of ischemia (Kamiya et al., 2008). The
significance of this study is, however, limited as the number of
animals was rather small (n = 5) and only one cell dose was
evaluated.
Therapies with cells of different sources were demonstrated
to exert anti-inflammatory actions after cerebral ischemia (Lee
et al., 2008; Schwarting et al., 2008). With respect to BM-MNC
treatment, immunomodulatory mechanisms post-stroke were
suggested based on in vitro investigations and on studies which
found a BM-MNC treatment associated reduction of proinflam-
matory cytokines (Brenneman et al., 2010; Sharma et al., 2010).
Our experiments, which investigated the local microglial immune
response, however, did not confirm that BM-MNCs reduce
this important element of post-stroke inflammation. A possible
explanation for these apparently different observations might be
that in the mentioned study cytokine levels of the whole brain
were measured (Brenneman et al., 2010). Since healthy animals
were used, infarct sizes were smaller after BM-MNC treatment
and this reduced volume of injured tissue in turn might be the
true reason for the lower cytokine concentrations.
Our study has strengths and limitations. The experiments
rigorously adhered to stringent quality criteria in experimental
stroke research such as randomization, surgery and evaluations
performed in a blinded fashion, and controlled physiological
parameters (Dirnagl, 2006; Kilkenny et al., 2011). Additionally,
the use of animals with a relevant comorbidity may increase
the predictive value of our findings regarding a human stroke
patient population. Studies with negative results have a poten-
tial general weakness, i.e., the type II error. The type II error
means that the null hypothesis is not rejected despite being false.
Applied to the present study BM-MNCs in fact would reduce
infarct volumes while not doing so in our experiments. However,
we performed a thorough a priori sample size calculation to
detect infarct size reductions of ≥20% with a statistical power
of 0.8 which corresponds to a type II error of 0.2. Moreover,
the use of a range of BM-MNC numbers should have prevented
to miss the efficacy of a specific cell dose. Another potential
limitation of our study is the generalizability. We cannot rule
out that an alternative procedure for cell preparation or the use
of healthy animals, animals of another strain or sex might have
yield different results. Our negative finding is therefore restricted
to the cell preparation, the route of transplantation and the
animal model used in this study. Particularly, the negative results
cannot attributed to the co-morbid condition of the animals
with certainty, since no control groups of healthy animals were
included.
Although neutral and negative experimental results are dis-
appointing at a first glance publishing those is certainly of great
importance when considering the tremendous costs of clinical
studies and the potential risks for patients. The present results
add relevant information to the pre-clinical development pro-
cess of BM-MNCs for stroke therapy. While using a clinically
meaningful model for post-stroke neuroprotection, we showed
that BM-MNCs do not improve outcome when given in the
early phase after the onset of ischemia. This may affect upcom-
ing efficacy studies in patients based on the rational that early
induction of BM-MNC therapy may lead to more favorable
outcomes.
Indubitably, previous animal experimental stroke studies
found improvements after BM-MNC therapy (Giraldi-Guimarães
et al., 2009; Brenneman et al., 2010; Nakano-Doi et al., 2010).
However, these studies initiated treatment beyond established
time windows of acute neuroprotection, thus potentially aim-
ing to restore neurological function by promoting regeneration
rather than protecting tissue at risk. Indeed, BM-MNCs can
also promote neurological recovery by enhancing neurogene-
sis and angiogenesis in later phases and were demonstrated
to stimulate brain remodeling processes, such as the prolifera-
tion of neural progenitor and endothelial cells, and to reduce
neurodegeneration (Giraldi-Guimarães et al., 2009; Nakano-Doi
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et al., 2010). Since the investigation of these later effects was
not in the focus of our investigation, a direct conclusion on
the impact of BM-MNC treatment at later stages following
experimental stroke may not be valid, but remains for fur-
ther study. However, the remarkable differences regarding acute
neuroprotection in healthy and comorbid animals as revealed
by the present study clearly underline the necessity to evalu-
ate relevant treatment effects and the optimal treatment time
window in animal models more adequately reflecting the sit-
uation of stroke patients. This will help to prepare large scale
efficacy studies with maximum rigor regarding our knowledge
on therapeutic mechanisms, and thereby efficacy in human
patients.
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